<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eleven men with <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> (HPAL; fasting plasma <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol level of &lt; 0.9 mmol/l), mild <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> (HTG; <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (TG) level of 1.75-7.5 mmol/l) and a <z:mpath ids='MPATH_458'>normal</z:mpath> calculated <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> level (&lt; 3.7 mmol/l) participated in a randomized, double-blind, double-placebo, crossover trial to compare the effect of two drugs, <z:chebi fb="0" ids="40303">lovastatin</z:chebi> (40 mg once daily) and <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> (600 mg twice daily), on clearance of postprandial <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>A 2-week washout period separated drug treatment periods of 6 weeks each </plain></SENT>
<SENT sid="2" pm="."><plain>Ten subjects completed each treatment period </plain></SENT>
<SENT sid="3" pm="."><plain>After ingestion of a vitamin A fat load, plasma, chylomicron and non-chylomicron <z:chebi fb="0" ids="15040">retinyl palmitate</z:chebi> (RP) and TG responses (areas under curves) were reduced in <z:hpo ids='HP_0000001'>all</z:hpo> subjects on <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> therapy and in 7 on <z:chebi fb="0" ids="40303">lovastatin</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>There was close correlation between change in fasting TG (but not fasting <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>) and change in postprandial RP areas on <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> but not <z:chebi fb="0" ids="40303">lovastatin</z:chebi> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Postheparin <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase (LPL) and hepatic lipase (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) activities were increased by <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> therapy while only a mild elevation in LPL activity alone was seen on <z:chebi fb="0" ids="40303">lovastatin</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that improvement in HTG is the main feature associated with improvement in postprandial <z:mp ids='MP_0001548'>lipemia</z:mp> and this is likely due to LPL-mediated enhancement of lipolytic hydrolysis </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="5296">Gemfibrozil</z:chebi> is more effective than <z:chebi fb="0" ids="40303">lovastatin</z:chebi> in attenuating postprandial <z:mp ids='MP_0001548'>lipemia</z:mp> in the HPAL/HTG syndrome </plain></SENT>
</text></document>